Scaling Access for Acute Allogeneic Cell Therapies: Lessons from Launch & Market Expansion
- Navigating transplant center access barriers unique to allogeneic cell therapies including cost committees’ quality reviews and operational assumptions to accelerate adoption
- Educating payers and Medicaid programs on acute treatment timelines for allogeneic therapies where patients need access in days not weeks
- Expanding delivery beyond major academic centers by enabling smaller transplant programs to confidently administer allogeneic cell therapies through new access education and distribution approaches